Pan-cancer single cell transcriptomic clustering reveals heterogeneous CD8+ exhausted T cell populations with different immune checkpoint inhibitor responses.

IF 6.5 2区 医学 Q1 IMMUNOLOGY
Oncoimmunology Pub Date : 2025-12-01 Epub Date: 2025-08-03 DOI:10.1080/2162402X.2025.2540504
Rui Mu, Rasha Barakat, David H Gutmann
{"title":"Pan-cancer single cell transcriptomic clustering reveals heterogeneous CD8<sup>+</sup> exhausted T cell populations with different immune checkpoint inhibitor responses.","authors":"Rui Mu, Rasha Barakat, David H Gutmann","doi":"10.1080/2162402X.2025.2540504","DOIUrl":null,"url":null,"abstract":"<p><p>In most cancers, T lymphocytes comprise an essential cellular component of the non-neoplastic microenvironment, where they have the capacity to both suppress and support tumor growth. One specialized T lymphocyte population is the CD8<sup>+</sup> exhausted T cell, which has been intensely studied as an actionable therapeutic target. Unfortunately, there is currently no uniformly accepted classification scheme for these specialized T cells. To provide a potential model for classifying CD8<sup>+</sup> exhausted T cells, we leveraged single cell transcriptomic analysis of a diverse collection of both human (<i>n</i> = 8) and mouse (<i>n</i> = 4) cancers to identify unique subpopulations shared across tumor types and species. By integrating data from both human and mouse cancer studies, as well as previously described CD8<sup>+</sup> exhausted T cell subsets, we provide an integrated framework to characterize the heterogeneity of exhausted CD8<sup>+</sup> T cells. As such, one of these subpopulations (cluster C1) increases following immune checkpoint inhibitor treatment in the setting of cancer in mice and patients. Taken together, this proposed classification scheme may be useful for the design and interpretation of current and future immune-based therapy studies.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"14 1","pages":"2540504"},"PeriodicalIF":6.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320814/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2025.2540504","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In most cancers, T lymphocytes comprise an essential cellular component of the non-neoplastic microenvironment, where they have the capacity to both suppress and support tumor growth. One specialized T lymphocyte population is the CD8+ exhausted T cell, which has been intensely studied as an actionable therapeutic target. Unfortunately, there is currently no uniformly accepted classification scheme for these specialized T cells. To provide a potential model for classifying CD8+ exhausted T cells, we leveraged single cell transcriptomic analysis of a diverse collection of both human (n = 8) and mouse (n = 4) cancers to identify unique subpopulations shared across tumor types and species. By integrating data from both human and mouse cancer studies, as well as previously described CD8+ exhausted T cell subsets, we provide an integrated framework to characterize the heterogeneity of exhausted CD8+ T cells. As such, one of these subpopulations (cluster C1) increases following immune checkpoint inhibitor treatment in the setting of cancer in mice and patients. Taken together, this proposed classification scheme may be useful for the design and interpretation of current and future immune-based therapy studies.

泛癌单细胞转录组聚类揭示了具有不同免疫检查点抑制剂反应的异质CD8+耗尽T细胞群。
在大多数癌症中,T淋巴细胞构成非肿瘤微环境的重要细胞成分,它们具有抑制和支持肿瘤生长的能力。一种特殊的T淋巴细胞群是CD8+耗竭T细胞,作为一种可行的治疗靶点已被广泛研究。不幸的是,对于这些特化的T细胞,目前还没有统一接受的分类方案。为了提供对CD8+耗竭T细胞进行分类的潜在模型,我们利用对人类(n = 8)和小鼠(n = 4)多种癌症的单细胞转录组学分析来识别跨肿瘤类型和物种共享的独特亚群。通过整合来自人类和小鼠癌症研究的数据,以及先前描述的CD8+耗尽T细胞亚群,我们提供了一个综合框架来表征耗尽CD8+ T细胞的异质性。因此,在小鼠和患者的癌症环境中,免疫检查点抑制剂治疗后,这些亚群之一(簇C1)增加。综上所述,这一分类方案可能对当前和未来免疫治疗研究的设计和解释有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
CiteScore
12.50
自引率
2.80%
发文量
276
审稿时长
24 weeks
期刊介绍: OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信